Swedish Orphan Biovitrum Japan Co., Ltd. (Sobi Japan) is the Japanese subsidiary of Swedish Orphan Biovitrum AB, a biopharmaceutical company focused on rare diseases. The unit supports the availability of specialty biologics and orphan therapies in Japan, with an emphasis on conditions in hematology, immunology, and selected genetic and metabolic disorders.
Sobi Japan’s activities include regulatory affairs, market access, pharmacovigilance, medical affairs, and post‑marketing surveillance in line with Japanese requirements. The company collaborates with healthcare providers, patient organizations, and global partners, and may participate in clinical studies and real‑world evidence initiatives to support the safe and effective use of its therapies.
Operating within Sobi’s global network, Sobi Japan focuses on compliance with PMDA and GxP standards and on ensuring continuity of supply and product quality for rare disease treatments in the Japanese market.
Also known as Sobi Japan.
First complement inhibitor in Japan for patients aged 12+ with these rare kidney diseases; VALIANT showed 68.1% proteinuria reduction and eGFR stabilization versus placebo.
